// App-Quantinova.ai

: Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.

Researchers

Presenter

  • Srikala S. Sridhar

Principal Investigators

  • Thomas Powles

  • Shilpa Gupta

  • Miguel Ángel Climent

  • Jeanny B. Aragon-Ching

  • Cora N. Sternberg

  • Paul Cislo

  • Nuno Costa

  • Alessandra Di Pietro

  • Joaquim Bellmunt

  • Petros Grivas

Medical Centers

  • Inova Schar Cancer Institute, Fairfax, VA

  • Weill Cornell Medicine, Hematology/Oncology, Englander Institute for Precision Medicine, Meyer Cancer Center, New York, NY

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Instiuto Valenciano de Oncologia, Valencia, Spain

  • Pfizer, Porto Salvo, Portugal

  • University of Washington, WA

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Pfizer Inc, New York, NY

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Barts Heart Centre, London, UK

  • Pfizer srl, Milano, Italy

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Locations

  • Portugal

  • Italy

  • Canada

  • Spain

  • United Kingdom

  • United States

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Carboplatin

  • Gemcitabine

  • Cisplatin

  • Avelumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02603432

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved